Search
Legend Biotech Corp
LEGNAdd to Watchlist
28.880USD
-0.510-1.74%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
5.36BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.74%
5 Days
-1.57%
1 Month
+6.33%
6 Months
+31.75%
Year to Date
+32.84%
1 Year
-16.60%
Key Figures
29.390Open
29.780High
1.02MVolume
LossP/E TTM
18.39P/E Dynamic
--Dividend TTM
0.55%Turnover Ratio
29.390Prev. Close
28.800Low
21.76MTurnover
LossP/E Static
5.54P/B
0.00%Div Yield TTM
-15.58%ROA
45.29752wk High
0.47Volume Ratio
-177.03MNet Profit
185.74MShares
-1.3544EPS TTM
0.36Beta
-25.20%ROE
16.24052wk Low
3.33%Amplitude
42.35%Gross Margin
5.36BMarket Cap
3.62Reward/Risk
4.20%Risk Rate
TradingKey Stock Score of Legend Biotech Corp
Currency: USD Updated: 2026-06-29Key Insights
Legend Biotech Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 54 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 59.55.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Legend Biotech Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Legend Biotech Corp Highlights
StrengthsRisks
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 260.84% year-on-year.
Fairly Valued
The company’s latest PE is -21.70, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 93.85M shares, decreasing 14.22% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 587.72K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.05.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
59.551
Target Price
+107.57%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Legend Biotech Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Legend Biotech Corp Info
Legend Biotech Corporation is a global biopharmaceutical company. The Company is engaged in the discovery, development, manufacturing and commercialization of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Ticker SymbolLEGN
CompanyLegend Biotech Corp
CEOHuang (Ying)
Websitehttps://investors.legendbiotech.com/
Related Instruments
-2.50%
-1.79%
-0.56%
-1.22%
-0.73%
-0.57%
+0.44%
-0.86%
+0.01%
-2.42%
-0.58%
-1.64%
-0.76%
-1.77%
+1.01%
0.00%
-1.31%
+1.68%
+0.56%
+0.28%Popular Instruments
52196.300
+43.100 (+0.08%)
30224.600
+516.900 (+1.74%)
7482.400
+50.200 (+0.68%)
15595.000
+144.000 (+0.93%)
70856.000
+382.000 (+0.54%)
6327.000
+71.200 (+1.14%)
69.921
-0.395 (-0.56%)
289.360
+7.620 (+2.70%)
200.090
+5.120 (+2.63%)
4007.280
-8.310 (-0.21%)
FAQs
What is the current price of Legend Biotech Corp (LEGN)?
The current price of Legend Biotech Corp (LEGN) is 29.39.
What is the symbol of Legend Biotech Corp?
The ticker symbol of Legend Biotech Corp is LEGN.
What is the 52-week high of Legend Biotech Corp?
The 52-week high of Legend Biotech Corp is 45.30.
What is the 52-week low of Legend Biotech Corp?
The 52-week low of Legend Biotech Corp is 16.24.
What is the market capitalization of Legend Biotech Corp?
The market capitalization of Legend Biotech Corp is 5.69B.
Is Legend Biotech Corp (LEGN) currently rated as Buy, Hold, or Sell?
According to analysts, Legend Biotech Corp (LEGN) has an overall rating of Buy, with a price target of 59.55.
What is the Earnings Per Share (EPS TTM) of Legend Biotech Corp (LEGN)?
The Earnings Per Share (EPS TTM) of Legend Biotech Corp (LEGN) is -1.61.
